Iron chelation: An update

Current Opinion in Hematology

Volumn 21, Issue 3, 2014, Pages 179-185

  Sheth, Sujit ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

combination therapy; deferasirox; deferiprone; new uses

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFERITAZOLE; DEFERITRIN; DEFEROXAMINE; IRON CHELATING AGENT; SSP 004184; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ARTHRALGIA; ARTHROPATHY; BETA THALASSEMIA; CATARACT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOPHOSPHATEMIA; INFECTION; IRON CHELATION; IRON OVERLOAD; LIVER FIBROSIS; LIVER TOXICITY; LOCAL SKIN REACTION; LONG QT SYNDROME; MEASUREMENT ACCURACY; MONITORING; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OPTIC NEURITIS; OTOTOXICITY; PERCEPTION DEAFNESS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; STEM CELL TRANSPLANTATION; THALASSEMIA; THALASSEMIA INTERMEDIA; VISUAL IMPAIRMENT; CHELATION THERAPY; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES;

CHELATION THERAPY; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING;

EID: 84899484076     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000031     Document Type: Review

References (51)

1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89:739-761.
2. Farmaki K, Tzoumari I, Pappa C, et al. Normalization of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2009; 148:466-475.
3. Kirk P, Roughton M, Porter JB, et al. Cardiac T2-magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120:1961-1968.
4. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010; 116:537-543.
5. Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006; 135:574-582.
6. Wood JC, Tyszka M, Carson S, et al. Myocardial iron loading in transfusiondependent thalassemia and sickle cell disease. Blood 2004; 103:1934-1936.
7. Roggero S, Quarello P, Vinciguerra T, et al. Severe iron overload in Blackfan-Diamond anemia: a case-control study. Am J Hematol 2009; 84:729-732.
8. Noetzli LJ, Mittelman SD, Watanabe RM, et al. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2012; 87:155-160.
9. Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol 2012; 87:167-171.
10. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of 30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009; 147:752-759.
11. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011; 118:884-893.
12. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010; 115:2364-2371.
13. Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2-in patients with b-thalassemia major. Haematologica 2012; 97:842-848.
14. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339:417-423.
15. Wanless IR, SweeneyG, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusiondependent beta-thalassemia. Blood 2002; 100:1566-1569.
16. Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28:196-208.
17. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107:3738-3744.
18. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 2006; 107:3733-3737.
19. Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005; 90:1309-1314.
20. Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy with deferiprone and deferoxamine: a 12-month trial. Blood Cells Mol Dis 2006; 36:21-25.
21. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115:1876-1884.
22. Link G, Konijn AM, Breuer W, et al. Exploring the 'iron shuttle' hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 138:130-138.
23. Porter JB, Wood J, Olivieri N, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson 2013; 15:38.
24. Otto-Duessel M, Brewer C, Gonzalez I, et al. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol 2008; 120:123-128.
25. Jetsrisuparb A, Komvilaisak P, Wiangnon S, Jetsrisuparb C. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. J Pediatr Hematol Oncol 2010; 32:400-403.
26. Voskaridou E, Komninaka V, Karavas A, et al. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with b-thalassemia major and severe iron burden. Transfusion 2013. doi: 10.1111/trf.12335. [Epub ahead of print]
27. Lal A, Porter J, Sweeters N, et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis 2013; 50:99-104.
28. Balocco M, Carrara P, Pinto V, Forni GL. Daily alternating deferasirox and deferiprone therapy for 'hard-to-chelate' beta-thalassemia major patients. Am J Hematol 2010; 85:460-461.
29. Berdoukas V, Carson S, Nord A, et al. Combining two orally active iron chelators for thalassemia. Ann Hematol 2010; 89:1177-1178.
30. Rienhoff HY Jr, Viprakasit V, Tay L, et al. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica 2011; 96:521-525.
31. Bergeron RJ, Wiegand J, Bharti N, et al. Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. Biometals 2011; 24:239-258.
32. Bergeron RJ, Wiegand J, Bharti N, McManis JS. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles. J Med Chem 2012; 55:7090-7103.
33. Galanello R. Recent advances in the molecular understanding of nontransfusion-dependent thalassemia. Blood Rev 2012; 26 (Suppl. 1):S7-S11.
34. Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in nontransfusion-dependent thalassemia: a clinical perspective. Blood Rev 2012; 26 (Suppl. 1):S16-S19.
35. Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in nontransfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol 2013; 92:1485-1493.
36. Leitch HA. Controversies surrounding iron chelation therapy for MDS. Blood Rev 2011; 25:17-31.
37. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006; 91:1588-1590.
38. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008; 83:765-770.
39. Chee CE, Steensma DP, Wu W, et al. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008; 83:611-613.
40. Jensen PD, Jensen IM, Ellegaard J, et al. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 1992; 80:121-124.
41. Messa E, Cilloni D, Messa F, et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008; 120:70-74.
42. Oliva EN, Ronco F, Marino A, et al. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion 2010; 50:1568-1570.
43. Guariglia R, MartorelliMC, Villani O, et al. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res 2011; 35:566-570.
44. Kikuchi S, Kobune M, Iyama S, et al. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radic Biol Med 2012; 53:643-648.
45. Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010; 34:1143-1150.
46. List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 2012; 30:2134-2139.
47. Nolte F, Hochsmann B, Giagounidis A, et al. Results from a 1-year, open-label, single arm, multicenter trial evaluating the efficacy and safety of oral deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol 2013; 92:191-198.
48. Altes A, Remacha AF, Sureda A, et al. Iron overload might increase transplantrelated mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29:987-989.
49. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109:4586-4588.
50. Mahindra A, Bolwell B, Sobecks R, et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009; 146:310-316.
51. Armand P, Sainvil MM, Kim HT, et al. Pretransplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant 2013; 48:146-147.